Metabolic & body composition
Single Regulator (GLP-1) — semaglutide
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending.
Semaglutide, listed as Single Regulator (GLP-1) because compounded formulations cannot be marketed under the drug's commercial name. A GLP-1 medication containing an active ingredient also found in FDA-approved products; compounded formulations are not themselves FDA-approved.
What it is
This is semaglutide, a GLP-1 receptor agonist. It mimics GLP-1, a gut hormone that slows gastric emptying, improves insulin response and reduces appetite signaling in the brain. The active ingredient is the same one found in FDA-approved products, but compounded formulations are not themselves FDA-approved and are dispensed only by licensed, FDA-registered compounding pharmacies after a physician evaluation.
What it's studied for
- Weight reduction of roughly 15% of body weight in the STEP program
- HbA1c and glycemic control in type 2 diabetes
- Cardiovascular event reduction in the SELECT trial
How it's used in practice
- Titrated slowly upward to limit gastrointestinal effects
- Muscle loss is the central risk of any GLP-1 — protein intake and resistance training are non-negotiable
- Off-ramp planning matters as much as the titration up
What you should know before asking about it
- Prescription only, after physician evaluation
- Contraindicated with personal or family history of medullary thyroid carcinoma or MEN2
- Nausea, constipation and reflux are common; pancreatitis is rare but serious
Frequently asked questions.
- What is Single Regulator (GLP-1) — semaglutide?
- This is semaglutide, a GLP-1 receptor agonist. It mimics GLP-1, a gut hormone that slows gastric emptying, improves insulin response and reduces appetite signaling in the brain. The active ingredient is the same one found in FDA-approved products, but compounded formulations are not themselves FDA-approved and are dispensed only by licensed, FDA-registered compounding pharmacies after a physician evaluation.
- What is Single Regulator (GLP-1) — semaglutide studied for?
- Published and ongoing research looks at weight reduction of roughly 15% of body weight in the STEP program; hbA1c and glycemic control in type 2 diabetes; cardiovascular event reduction in the SELECT trial. These are areas of study, not promised outcomes.
- Is Single Regulator (GLP-1) — semaglutide FDA-approved?
- Single Regulator (GLP-1) — semaglutide is not FDA-approved as a finished product. It is prepared by licensed, FDA-registered compounding pharmacies and can be dispensed only on a prescription written after a physician evaluation.
- How is Single Regulator (GLP-1) — semaglutide typically used?
- Titrated slowly upward to limit gastrointestinal effects Muscle loss is the central risk of any GLP-1 — protein intake and resistance training are non-negotiable Off-ramp planning matters as much as the titration up Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.
- What are the risks and unknowns with Single Regulator (GLP-1) — semaglutide?
- Prescription only, after physician evaluation Contraindicated with personal or family history of medullary thyroid carcinoma or MEN2 Nausea, constipation and reflux are common; pancreatitis is rare but serious
Sources
- 1.Published literature on Single Regulator (GLP-1) — semaglutide— PubMed, U.S. National Library of Medicine
- 2.Compounding and the FDA: questions and answers— U.S. Food & Drug Administration
- 3.Bulk drug substances nominated for use in compounding under section 503A— U.S. Food & Drug Administration
- 4.Test directory and patient service center locator— Quest Diagnostics
About this page
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending. Educational content only — not medical advice, not a diagnosis, and not an offer to sell any prescription product.
This page is educational reference material. It is not medical advice, not a diagnosis, and not an offer to sell any product. Prescription therapies are dispensed only through licensed, FDA-registered compounding pharmacies after a physician evaluation. Compounds identified as research use only are not FDA-approved, are not prescribed as medical care, and are not intended for human or animal consumption. Availability, formulations and regulatory status change over time.
More in Metabolic & body composition
Dual Regulator (GLP-1/GIP) — tirzepatide
Tirzepatide, listed as Dual Regulator (GLP-1/GIP) because compounded formulations cannot be marketed under the drug's commercial name. A GIP/GLP-1 medication containing an active ingredient also found in FDA-approved products; compounded formulations are not themselves FDA-approved.
Triple Regulator (GLP-1/GIP/glucagon)
An investigational triple agonist (GLP-1, GIP and glucagon) in late-stage clinical trials — not approved, not prescribable.
AOD-9604
A fragment of human growth hormone studied for fat metabolism without the growth-signaling effects of full HGH.